Nanoparticle-mediated pulmonary drug delivery: A review

International Journal of Molecular Sciences

Volumn 15, Issue 4, 2014, Pages 5852-5873

  Paranjpe, Mukta ^a   Müller Goymann, Christel C ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Aerosol; Lung cell models; Lung disease; Nanoparticles; Nebulization; SLN; Toxicity

Indexed keywords

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; ANTIOXIDANT; BECLOMETASONE; BUDESONIDE; CALCITONIN; CIPROFLOXACIN; CISPLATIN; CLARITHROMYCIN; CURCUMIN; DOXORUBICIN; FLUTICASONE; HEPARIN; INDOMETACIN; INSULIN; ITRACONAZOLE; METHOTREXATE; MOXIFLOXACIN; NANOPARTICLE; OFLOXACIN; PACLITAXEL; PIRFENIDONE; SILIBININ; TACROLIMUS; TECHNETIUM 99M; TOBRAMYCIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE; ANTIASTHMATIC AGENT; ANTINEOPLASTIC AGENT; COLLOID; LIPID; LIPOSOME; NANOCAPSULE; NANOCONJUGATE; POLYMER;

ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; CELL CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; EPITHELIUM CELL; HUMAN; LASER DIFFRACTION; LUNG GAS EXCHANGE; MEMBRANE MICROPARTICLE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZES; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; REVIEW; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; ANIMAL MODEL; COLLOID; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTINEOPLASTIC AGENTS; COLLOIDS; HUMANS; LIPIDS; LIPOSOMES; LUNG DISEASES; MODELS, ANIMAL; NANOCAPSULES; NANOCONJUGATES; POLYMERS;

EID: 84898652900     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15045852     Document Type: Review

References (101)

1. Azarmi, S.; Roa, W.H.; Löbenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008, 60, 863-875.
2. Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 25, 563-570.
3. Jaafar-Maalej, C.; Elaissari, A.; Fessi, H. Lipid-based carriers: Manufacturing and applications for pulmonary route. Expert Opin. Drug Deliv. 2012, 9, 1111-1127.
4. Beck-Broichsitter, M.; Gauss, J.; Packhaeuser, C.B.; Lahnstein, K.; Schmehl, T.; Seeger, W.; Kissel, T.; Gessler, T. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int. J. Pharm. 2009, 367, 169-178.
5. Beck-Broichsitter, M.; Kleimann, P.; Gessler, T.; Seeger, W.; Kissel, T.; Schmehl, T. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: Formulation aspects and nanoparticle stability to nebulization. Int. J. Pharm. 2012, 422, 398-408.
6. Mueller, R. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161-177.
7. Mueller, R. Lipid nanoparticles: Recent advances. Adv. Drug Deliv. Rev. 2007, 59, 375-376.
8. Nassimi, M.; Schleh, C.; Lauenstein, H.; Hussein, R.; Hoymann, H.; Koch, W.; Pohlmann, G.; Krug, N.; Sewald, K.; Rittinghausen, S., et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 2010, 75, 107-116.
9. Nassimi, M.; Schleh, C.; Lauenstein, H.-D.; Hussein, R.; Lübbers, K.; Pohlmann, G.; Switalla, S.; Sewald, K.; Müller, M.; Krug, N., et al. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhal. Toxicol. 2009, 21, 104-109.
10. Paranjpe, M.; Neuhaus, V.; Finke, J.H.; Richter, C.; Gothsch, T.; Kwade, A.; Büttgenbach, S.; Braun, A.; Müller-Goymann, C.C. In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles. Inhal. Toxicol. 2013, 25, 536-543.
11. Menon, J.U.; Ravikumar, P.; Pise, A.; Gyawali, D.; Hsia, C.C.W.; Nguyen, K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater. 2014, in press, doi:10.1016/j.actbio.2014.01.033.
12. Menon, J.U.; Wadajkar, A.S.; Xie, Z.; Nguyen, K.T. Nanomaterials for management of lung disorders and drug delivery. In Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering; Tiwari, A., Tiwari, A., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2013; pp. 167-202.
13. Patel, P.; Soni, T.; Thakkar, V.; Gandhi, T. Nanoparticle as an emerging tool in pulmonary drug delivery system. MNS 2013, 5, 288-302.
14. Rang, H.P.; Dale, M.M.; Ritter, J.M.; Flower, R.J. Pharmacology, Sixth ed.; Churchill Livingstone: New York, NY, USA, 2007; Section 3, Chapter 22.
15. Kelly, L. Essentials of Human Physiology for Pharmacy; CRC Press: Boca Raton, FL, USA, 2004.
16. Tena, A.F.; Clarà, P.C. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012, 48, 240-246.
17. Yang, W.; Peters, J.I.; Williams, R.O. Inhaled nanoparticles-A current review. Int. J. Pharm. 2008, 356, 239-247.
18. Patton, J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 1996, 19, 3-36.
19. Patton, J.S.; Brain, J.D.; Davies, L.A.; Fiegel, J.; Gumbleton, M.; Kim, K.-J.; Sakagami, M.; Vanbever, R.; Ehrhardt, C. The particle has landed-Characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23, S71-S87.
20. Beck-Broichsitter, M.; Ruppert, C.; Schmehl, T.; Guenther, A.; Betz, T.; Bakowsky, U.; Seeger, W.; Kissel, T.; Gessler, T. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomed. Nanotechnol. Biol. Med. 2011, 7, 341-350.
21. Silva, L.F.C.; Kasten, G.; de Campos, C.E.M.; Chinelatto, A.L.; Lemos-Senna, E. Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. Powder Technol. 2013, 239, 183-192.
22. Wang, W.; Zhu, R.; Xie, Q.; Li, A.; Xiao, Y.; Liu, H.; Wang, S.; Cui, D. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. IJN 2012, 7, 3667-3677.
23. Varshosaz, J.; Ghaffari, S.; Mirshojaei, S.F.; Jafarian, A.; Atyabi, F.; Kobarfard, F.; Azarmi, S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed. Res. Int. 2013, 2013, 1-8.
24. Mussi, S.V.; Silva, R.C.; Oliveira, M.C.; Lucci, C.M.; Azevedo, R.B.; Ferreira, L.A.M. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur. J. Pharm. Sci. 2013, 48, 282-290.
25. Chiraz, J.-M.; Andrieu, V.; Elaissari, A.; Fessi, H. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: Preparation, characterization and in vitro drug release. J. Nanosci. Nanotechnol. 2011, 11, 1841-1851.
26. Elhissi, A.; Islam, M.A.; Arafat, B.; Taylor, M.; Ahmed, W. Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs. Micro Nano Lett. 2010, 5, 184.
27. Zhang, P.-R.; Xie, Y.; Li, M. Preparation and characterization of budesonide-loaded solid lipid nanoparticles for pulmonary delivery. J. Chin. Pharm. Sci. 2011, 20, 390-396.
28. Kumar, S.S.D.; Surianarayanan, M.; Vijayaraghavan, R.; Mandal, A.B.; MacFarlane, D.R. Curcumin loaded poly(2-hydroxyethyl methacrylate) nanoparticles from gelled ionic liquid-In vitro cytotoxicity and anti-cancer activity in SKOV-3 cells. Eur. J. Pharm. Sci. 2014, 51, 34-44.
29. Castelli, F.; Puglia, C.; Sarpietro, M.G.; Rizza, L.; Bonina, F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int. J. Pharm. 2005, 304, 231-238.
30. Ali, R.; Mittal, G.; Ali, R.; Kumar, M.; Kishan Khar, R.; Ahmad, F.J.; Bhatnagar, A. Development, characterisation and pharmacoscintigraphic evaluation of nano-fluticasone propionate dry powder inhalation as potential antidote against inhaled toxic gases. J. Microencapsul. 2013, 30, 546-558.
31. Trivedi, R.; Redente, E.F.; Thakur, A.; Riches, D.W.H.; Kompella, U.B. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 2012, 23, 505101.
32. Rao, A.K.; Shrikhande, S.; Bajaj, A. Development of cisplatin nanoparticles as dry powder inhalers for lung cancer. Curr. Nanosci. 2013, 9, 447-450.
33. Roa, W.H.; Azarmi, S.; Al-Hallak, M.K.; Finlay, W.H.; Magliocco, A.M.; Löbenberg, R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release 2011, 150, 49-55.
34. Li, M. Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe3O4 magnetic nanoparticles for targeted anticancer effects. Eur. J. Pharm. Sci. 2013, 48, 111-120.
35. Gill, K.K.; Nazzal, S.; Kaddoumi, A. Paclitaxel loaded PEG5000-DSPE micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur. J. Pharm. Biopharm. 2011, 79, 276-284.
36. Chen, H.; Zhao, T.; Dong, Y.; Zhang, J.; Huang, H.; Zhu, J. Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy. IJN 2013, 8, 1947-1957.
37. Yang, R.; Yang, S.-G.; Shim, W.-S.; Cui, F.; Cheng, G.; Kim, I.-W.; Kim, D.-D.; Chung, S.-J.; Shim, C.-K. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J. Pharm. Sci. 2009, 98, 970-984.
38. Xu, P.; Yin, Q.; Shen, J.; Chen, L.; Yu, H.; Zhang, Z.; Li, Y. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int. J. Pharm. 2013, 454, 21-30.
39. Yoo, D.; Guk, K.; Kim, H.; Khang, G.; Wu, D.; Lee, D. Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases. Int. J. Pharm. 2013, 450, 87-94.
40. Hoesel, L.M.; Flierl, M.A.; Niederbichler, A.D.; Rittirsch, D.; McClintock, S.D.; Reuben, J.S.; Pianko, M.J.; Stone, W.; Yang, H.; Smith, M., et al. Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Antioxid. Redox Signal. 2008, 10, 963-972.
41. Arikace Website Source. Available online: http://www.insmed.com/product-candidates/about-arikace (accessed on 9 January 2014).
42. Cipolla, D.; Gonda, I.; Chan, H.-K. Liposomal formulations for inhalation. Ther. Deliv. 2013, 4, 1047-1072.
43. Adler-Moore, J.; Proffitt, R.T. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 2002, 49, 21-30.
44. Pandey, R. Antitubercular inhaled therapy: Opportunities, progress and challenges. J. Antimicrob. Chemother.2005, 55, 430-435.
45. Zhang, L.; Pornpattananangkul, D.; Hu, C.-M.; Huang, C.-M. Development of nanoparticles for antimicrobial drug delivery. CMC 2010, 17, 585-594.
46. Behr, J.; Zimmermann, G.; Baumgartner, R.; Leuchte, H.; Neurohr, C.; Brand, P.; Herpich, C.; Sommerer, K.; Seitz, J.; Menges, G., et al. Lung deposition of a liposomal cyclosporine a inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22, 121-130.
47. Muttil, P.; Kaur, J.; Kumar, K.; Yadav, A.B.; Sharma, R.; Misra, A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 2007, 32, 140-150.
48. Salomon, J.J.; Galeron, P.; Schulte, N.; Morow, P.R.; Severynse-Stevens, D.; Huwer, H.; Daum, N.; Lehr, C.-M.; Hickey, A.J.; Ehrhardt, C. Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Ther. Deliv. 2013, 4, 915-923.
49. Manca, M.; Sinico, C.; Maccioni, A.; Diez, O.; Fadda, A.; Manconi, M. Composition influence on pulmonary delivery of rifampicin liposomes. Pharmaceutics 2012, 4, 590-606.
50. Chimote, G.; Banerjee, R. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J. Biomed. Mater. Res. 2010, 94B, 1-10.
51. Chuan, J.; Li, Y.; Yang, L.; Sun, X.; Zhang, Q.; Gong, T.; Zhang, Z. Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles. J. Nanopart. Res. 2013, 15, doi:10.1007/s11051-013-1634-1.
52. Hadinoto, K.; Cheow, W.S. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf. B Biointerfaces 2014, in press, doi:10.1016/j.colsurfb.2014.02.032.
53. Gupta, A.; Pandya, S.M.; Mohammad, I.; Agrawal, A.K.; Mohan, M.; Misra, A. Particulate pulmonary delivery systems containing anti-tuberculosis agents. Crit. Rev. Ther. Drug Carr. Syst. 2013, 30, 277-291.
54. Pulmaquin Website Source. Available online: http://investor.aradigm.com/releasedetail.cfm?releaseid=630968 (accessed on 9 January 2014).
55. Liu, C.; Shi, J.; Dai, Q.; Yin, X.; Zhang, X.; Zheng, A. In-vitro and in-vivo evaluation of ciprofloxacin liposome for pulmonary administration. Drug Dev. Ind. Pharm. 2013, 1-7, doi:10.3109/03639045.2013.858740.
56. Duan, J.; Vogt, F.G.; Li, X.; Hayes, D.; Mansour, H.M. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int. J. Nanomed. 2013, 8, 3489-3505.
57. Pilcer, G.; Rosière, R.; Traina, K.; Sebti, T.; Vanderbist, F.; Amighi, K. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J. Pharm. Sci. 2013, 102, 1836-1846.
58. Park, C.-W.; Li, X.; Vogt, F.G.; Hayes, D.; Zwischenberger, J.B.; Park, E.-S.; Mansour, H.M. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int. J. Pharm. 2013, 455, 374-392.
59. Moghaddam, P.H.; Ramezani, V.; Esfandi, E.; Vatanara, A.; Nabi-Meibodi, M.; Darabi, M.; Gilani, K.; Najafabadi, A.R. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol. 2013, 239, 478-483.
60. Sinha, B.; Mukherjee, B.; Pattnaik, G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: In vitro and in vivo study. Nanomedicine 2013, 9, 94-104.
61. Wu, X.; Hayes, D.; Zwischenberger, J.B.; Kuhn, R.J.; Mansour, H.M. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des. Dev. Ther. 2013, 7, 59-72.
62. Pardeike, J.; Weber, S.; Haber, T.; Wagner, J.; Zarfl, H.P.; Plank, H.; Zimmer, A. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int. J. Pharm. 2011, 419, 329-338.
63. Duret, C.; Wauthoz, N.; Sebti, T.; Vanderbist, F.; Amighi, K. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int. J. Nanomed. 2012, 7, 5475-5489.
64. Takeuchi, H.; Sugihara, H. Absorption of calcitonin in oral and pulmonary administration with polymer-coated liposomes. Yakugaku Zasshi 2010, 130, 1135-1142.
65. Murata, M.; Yonamine, T.; Tanaka, S.; Tahara, K.; Tozuka, Y.; Takeuchi, H. Surface modification of liposomes using polymer-wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration. J. Pharm. Sci. 2013, 102, 1281-1289.
66. Trapani, A.; di Gioia, S.; Ditaranto, N.; Cioffi, N.; Goycoolea, F.M.; Carbone, A.; Garcia-Fuentes, M.; Conese, M.; Alonso, M.J. Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles. Int. J. Pharm. 2013, 447, 115-123.
67. Liu, J.; Gong, T.; Fu, H.; Wang, C.; Wang, X.; Chen, Q.; Zhang, Q.; He, Q.; Zhang, Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 2008, 356, 333-344.
68. Zhao, Y.-Z.; Li, X.; Lu, C.-T.; Xu, Y.-Y.; Lv, H.-F.; Dai, D.-D.; Zhang, L.; Sun, C.-Z.; Yang, W.; Li, X.-K., et al. Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol. 2012, 49, 315-325.
69. Lee, C.; Choi, J.S.; Kim, I.; Oh, K.T.; Lee, E.S.; Park, E.-S.; Lee, K.C.; Youn, Y.S. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int. J. Nanomed. 2013, 8, 2975-2983.
70. Kleemann, E.; Schmehl, T.; Gessler, T.; Bakowsky, U.; Kissel, T.; Seeger, W. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: Formulation aspects and stability. Pharm. Res. 2007, 24, 277-287.
71. Beck-Broichsitter, M.; Schmehl, T.; Gessler, T.; Seeger, W.; Kissel, T. Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. J. Control. Release 2012, 157, 469-477.
72. Varshosaz, J.; Taymouri, S.; Hamishehkar, H. Fabrication of polymeric nanoparticles of poly(ethylene-co-vinyl acetate) coated with chitosan for pulmonary delivery of carvedilol. J. Appl. Polym. Sci. 2014, 131, doi:10.1002/app.39694.
73. Park, S.; Jeong, E.J.; Lee, J.; Rhim, T.; Lee, S.K.; Lee, K.Y. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydr. Polym. 2013, 92, 57-62.
74. Sharma, K.; Somavarapu, S.; Colombani, A.; Govind, N.; Taylor, K.M.G. Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery. Int. J. Pharm. 2013, 455, 241-247.
75. Beck-Broichsitter, M.; Ruppert, C.; Schmehl, T.; Günther, A.; Seeger, W. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles. Biochim. Biophys. Acta 2013, 1838, 474-481.
76. Rudiger, M. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. AJP: Lung Cell. Mol. Physiol. 2004, 288, L379-L383.
77. Veldhuizen, R.; Nag, K.; Orgeig, S.; Possmayer, F. The role of lipids in pulmonary surfactant. Biochim. Biophys. Acta 1998, 1408, 90-108.
78. Wood, A.J.; Jobe, A.H. Pulmonary surfactant therapy. N. Engl. J. Med. 1993, 328, 861-868.
79. Willis, L.; Hayes, D.; Mansour, H.M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012, 190, 251-262.
80. Ribeiro, A.M.; Souza, A.C.O.; Amaral, A.C.; Vasconcelos, N.M.; Jerônimo, M.S.; Carneiro, F.P.; Faccioli, L.H.; Felipe, M.S.S.; Silva, C.L.; Bocca, A.L. Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection. J. Biomed. Nanotechnol. 2013, 9, 221-230.
81. Srinivasan, A.R.; Shoyele, S.A. Self-associated submicron IgG1 particles for pulmonary delivery: Effects of non-ionic surfactants on size, shape, stability, and aerosol performance. AAPS PharmSciTech 2013, 14, 200-210.
82. Rampino, A.; Borgogna, M.; Blasi, P.; Bellich, B.; Cesàro, A. Chitosan nanoparticles: Preparation, size evolution and stability. Int. J. Pharm. 2013, 455, 219-228.
83. Gaspar, M.M.; Bakowsky, U.; Ehrhardt, C. Inhaled liposomes-Current strategies and future challenges. J. Biomed. Nanotechnol. 2008, 4, 245-257.
84. Cipolla, D.; Wu, H.; Eastman, S.; Redelmeier, T.; Gonda, I.; Chan, H.-K. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J. Pharm. Sci. 2014, 103, 314-327.
85. Clancy, J.P.; Dupont, L.; Konstan, M.W.; Billings, J.; Fustik, S.; Goss, C.H.; Lymp, J.; Minic, P.; Quittner, A.L.; Rubenstein, R.C., et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68, 818-825.
86. Hood, E.D.; Chorny, M.; Greineder, C.F.; Alferiev, I.S.; Levy, R.J.; Muzykantov, V.R. Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. Biomaterials 2014, 35, 3708-3715.
87. Bunjes, H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 2010, 62, 1637-1645.
88. Bunjes, H. Structural properties of solid lipid based colloidal drug delivery systems. Curr. Opin. Colloid Interface Sci. 2011, 16, 405-411.
89. Bunjes, H.; Unhruh, T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev. 2007, 59, 379-402.
90. Ehrhardt, C.; Kim, K.-J.; Lehr, C.-M. Human cell culture protocols: Isolation and culture of human alveolar epithelial cells. Methods Mol. Med. 2004, 15, 207-216.
91. Ehrhardt, C.; Laue, M.; Kim, K.-J. In vitro models of the alveolar epithelial barrier. In Drug Absorption Studies; Springer US: Boston, MA, USA, 2008; pp. 258-282.
92. Forbes, B.; Shah, A.; Martin, G.P.; Lansley, A.B. The human bronchial epithelial cell line 16HBE14o-as a model system of the airways for studying drug transport. Int. J. Pharm. 2003, 257, 161-167.
93. Scherließ, R. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. Int. J. Pharm. 2011, 411, 98-105.
94. Sakagami, M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 2006, 58, 1030-1060.
95. Foster, K.A.; Avery, M.L.; Yazdanian, M.; Audus, K.L. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 2000, 208, 1-11.
96. Neuhaus, V.; Schwarz, K.; Klee, A.; Seehase, S.; Förster, C.; Pfennig, O.; Jonigk, D.; Fieguth, H.-G.; Koch, W.; Warnecke, G., et al. Functional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice technique. PLoS One 2013, 8, e71728.
97. Kaneko, M.; Coppen, S.R. Histological validation of heart slices as a model in cardiac research. J. Cell Sci. Ther. 2012, 3, doi:10.4172/2157-7013.1000126.
98. Wang, T.; Liu, Y.; Chen, L.; Wang, X.; Hu, X.-R.; Feng, Y.-L.; Liu, D.-S.; Xu, D.; Duan, Y.-P.; Lin, J., et al. Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur. Respir. J. 2009, 33, 1122-1132.
99. Knapp, S. LPS and bacterial lung inflammation models. Drug Discov. Today: Dis. Models 2009, 6, 113-118.
100. Marsboom, G.R.; Janssens, S.P. Models for pulmonary hypertension. Drug Discov. Today: Dis. Models 2004, 1, 289-296.
101. Arora, S.; Rajwade, J.M.; Paknikar, K.M. Nanotoxicology and in vitro studies: The need of the hour. Toxicol. Appl. Pharm. 2012, 258, 151-165.